Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Bavarian Nordic A/S
  6. News
  7. Summary
    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-09-30 am EDT
222.70 DKK   +4.26%
09/26UK Government To Offer Second Doses Of Bavarian Nordic's Monkeypox Vaccine To People At Highest Risk
MT
09/20Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
GL
09/20Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

06/16/2022 | 05:32am EDT

Bavarian Nordic A/S provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include a licensed mRNA-based vaccine (Comirnaty®) in the comparator arm of the study, to potentially support the primary objective of the study and demonstrate that the neutralizing antibodies induced by ABNCoV2 are non-inferior to the levels stimulated by the licensed mRNA-based vaccine. The addition of the comparator vaccine for clinical trial use has now been made possible in cooperation with regulatory authorities and vaccine manufacturers, and enables Bavarian Nordic to conduct a double-blind, controlled Phase 3 trial.

The Phase 3 trial will enroll approximately 4,000 adult subjects who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19 vaccine. The trial consists of two groups, which will run in parallel. The active, controlled group will enroll 1,000 subjects who will be randomized to receive either a single 100 µg dose of ABNCoV2 or a single 30 µg adult booster dose of Comirnaty.

The other group will evaluate the safety and tolerability of the vaccine in 3,000 subjects who will receive a single 100 µg dose of ABNCoV2. Based on the new design, the Phase 3 trial will now start enrolling in August 2022, but the overall timelines for trial remain unaffected. Thus, the Company still anticipates the initial data read-out before the end of 2022, which will allow for a rolling submission to the regulatory authorities, aiming to obtain approval of the vaccine in 2023.


© S&P Capital IQ 2022
All news about BAVARIAN NORDIC A/S
09/26UK Government To Offer Second Doses Of Bavarian Nordic's Monkeypox Vaccine To People At..
MT
09/20Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
GL
09/20Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
GL
09/20Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors
CI
09/20European Midday Briefing: Stocks Struggle; Riksbank Surprises w..
DJ
09/20Bavarian Nordic Wins Updated $434 Million Order For Monkeypox Jab From Canadian Governm..
MT
09/20Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for th..
GL
09/20Bavarian Nordic Receives Ten-Year Contract Amendment Valued Up to USD 434 Million for t..
CI
09/20BAVARIAN NORDIC A/S : Changes in management and corporate officers
CO
09/14Take whatever COVID vaccine you can get, says head of EU drugs watchdog
RE
More news
Analyst Recommendations on BAVARIAN NORDIC A/S
More recommendations
Financials
Sales 2022 3 125 M 412 M 412 M
Net income 2022 -445 M -58,6 M -58,6 M
Net cash 2022 2 153 M 284 M 284 M
P/E ratio 2022 -34,9x
Yield 2022 -
Capitalization 15 711 M 2 070 M 2 070 M
EV / Sales 2022 4,34x
EV / Sales 2023 1,53x
Nbr of Employees 868
Free-Float 99,8%
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 222,70 DKK
Average target price 429,86 DKK
Spread / Average Target 93,0%
EPS Revisions
Managers and Directors
Paul Chaplin President & Chief Executive Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Gerardus Wilhelmus van Odijk Chairman
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Russell Thirsk Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BAVARIAN NORDIC A/S-17.15%2 070
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296